TEE
CLVS

Tibra Equities Europe’s Clovis Oncology, Inc. CLVS Stock Holding History

Tibra Equities Europe’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-27,300
Closed -$406K – 367
2019
Q2 		$406K Buy
+27,300
New +$493K 0.03% 199

Other funds holding CLVS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Tibra Equities Europe's CLVS Position: Q3 2019 in Review

Tibra Equities Europe sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 27,300 shares — an estimated $406K sold.

Tibra Equities Europe first reported a position in CLVS in Q2 2019 and held it in 1 quarter. The position peaked at $406K in Q2 2019. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

  • Tibra Equities Europe reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 27,300 Clovis Oncology, Inc. shares in Q3 2019, an estimated $406K.
  • Tibra Equities Europe first reported a position in Clovis Oncology, Inc. in Q2 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Clovis Oncology, Inc. position peaked at $406K in Q2 2019.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Tibra Equities Europe's 13F filing for Q3 2019, filed 4 Nov 2019.